Prothrombin complex concentrates: a brief review.

Eur J Anaesthesiol

Hotel-Dieu University Hospital, Department of Anaesthesiology and Intensive Care, Paris Cedex, France.

Published: October 2008

Prothrombin complex concentrates are haemostatic blood products containing four vitamin K-dependent clotting factors (II, VII, IX and X). They are a useful, reliable and fast alternative to fresh frozen plasma for the reversal of the effects of oral anticoagulant treatments (vitamin K antagonists). They are sometimes used for factor II or factor X replacement in patients with congenital or acquired deficiencies. They are widely prescribed in Europe. Several retrospective and prospective studies have demonstrated their efficacy in normalizing coagulation and in helping to control life-threatening bleeding. Few side-effects, mainly thromboembolic events, have been reported. The link between these events and prothrombin complex concentrate infusion has, however, often been brought into question. The use of prothrombin complex concentrates in new promising indications such as the management of massive bleeding requires prospective studies providing a high level of evidence in a high-risk setting.

Download full-text PDF

Source
http://dx.doi.org/10.1017/S0265021508004675DOI Listing

Publication Analysis

Top Keywords

prothrombin complex
16
complex concentrates
12
prospective studies
8
prothrombin
4
concentrates review
4
review prothrombin
4
concentrates haemostatic
4
haemostatic blood
4
blood products
4
products vitamin
4

Similar Publications

Hepatocyte carcinoma (HCC) is a globally prevalent neoplasm with profound effects on morbidity and mortality rates. This review summarizes the complex interactions between coagulation abnormalities and the pathophysiological mechanisms underlying HCC. Essential coagulation biomarkers, such as P-selectin, thrombomodulin, d-dimer, prothrombin, and von Willebrand factor, are reviewed for their diagnostic, prognostic, and therapeutic significance.

View Article and Find Full Text PDF

Factor XIa Inhibitor Reversal in Intracranial Hemorrhage: A Case Report.

Neurohospitalist

January 2025

Department of Neurology, Division of Neurocritical Care, University of North Carolina, Chapel Hill, NC, USA.

Background/objectives: There is currently no consensus regarding the optimal strategy for reversal of anticoagulation in life-threatening hemorrhage associated with factor XIa (FXIa) inhibitors.

Methods: For this clinical case report, informed consent was obtained from surrogate.

Results And Discussion: Here, we present the case of an 82-year-old female who sustained a large subdural hematoma after a fall.

View Article and Find Full Text PDF

Serious issues with cryo-EM structures of human prothrombinase.

Open Biol

January 2025

Department of Haematology, Cambridge Institute for Medical Research, University of Cambridge, The Keith Peters Building, Hills Road , Cambridge CB2 0XY, UK.

Thrombin is generated from prothrombin through sequential cleavage at two sites by the enzyme complex prothrombinase, composed of a serine protease, factor (f) Xa and a cofactor, fVa, on phospholipid membranes. In a recent paper published in , Ruben . (Ruben .

View Article and Find Full Text PDF

Congenital factor VII (FVII) deficiency is a rare coagulation disorder that increases the risk of bleeding complications during surgery. Although laparoscopic sleeve gastrectomy (LSG) is the most common metabolic bariatric surgery (MBS), it is rarely performed in patients with congenital coagulation disorders such as FVII deficiency, due to the high risk of intraoperative and postoperative bleeding. We report the case of a 57-year-old female with class II obesity (BMI 37.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!